Tenecteplase versus alteplase for acute stroke within 4.5h of onset: the second alteplase-tenecteplase trial evaluation for stroke thrombolysis (ATTEST-2)
The results of a major stroke trial presented at the World Stroke Congress in Toronto today, has demonstrated the potential of a new treatment for stroke which could help patients make a better recovery.
Stroke is a leading cause of death and disability. There are 100,000 strokes each year, and 1.3 million stroke survivors in the UK. For every minute left untreated 1.9 million brain cells die.
